Clinical differentiation of acute myocardial infarction (MI) from unstable angina and other presentations mimicking acute coronary syndromes (ACS) is critical for implementing time-sensitive interventions and optimizing outcomes. However, the diagnostic steps are dependent on blood draws and laboratory turnaround times. We tested the clinical feasibility of a wrist-worn transdermal infrared spectrophotometric sensor (transdermal-ISS) in clinical practice and assessed the performance of a machine learning algorithm for identifying elevated high-sensitivity cardiac troponin-I (hs-cTnI) levels in patients hospitalized with ACS. We enrolled 238 patients hospitalized with ACS at five sites. The final diagnosis of MI (with or without ST elevation) and unstable angina was adjudicated using electrocardiography (ECG), cardiac troponin (cTn) test, echocardiography (regional wall motion abnormality), or coronary angiography. A transdermal-ISS–derived deep learning model was trained (three sites) and externally validated with hs-cTnI (one site) and echocardiography and angiography (two sites), respectively. The transdermal-ISS model predicted elevated hs-cTnI levels with areas under the receiver operator characteristics of 0.90 [95% confidence interval (CI), 0.84–0.94; sensitivity, 0.86; and specificity, 0.82] and 0.92 (95% CI, 0.80–0.98; sensitivity, 0.94; and specificity, 0.64), for internal and external validation cohorts, respectively. In addition, the model predictions were associated with regional wall motion abnormalities [odds ratio (OR), 3.37; CI, 1.02–11.15; P = 0.046] and significant coronary stenosis (OR, 4.69; CI, 1.27–17.26; P = 0.019). A wrist-worn transdermal-ISS is clinically feasible for rapid, bloodless prediction of elevated hs-cTnI levels in real-world settings. It may have a role in establishing a point-of-care biomarker diagnosis of MI and impact triaging patients with suspected ACS. The study evaluated a wrist-worn troponin-I sensor in hospitalized ACS patients with paired venous blood obtained for centralized troponin-I assay. A deep learning model was developed using the optical data from three training sites and externally validated for predicting elevated hs-cTnI (one site) levels and clinically associated with obstructive CAD and regional wall motion abnormalities (two sites).
We examined the changes in variables that could be recorded on wearable devices during the early stages of acute myocardial infarction (AMI) in an animal model. Early diagnosis of AMI is important for prognosis; however, delayed diagnosis is common because of patient hesitation and lack of timely evaluations. Wearable devices are becoming increasingly sophisticated in the ability to track indicators. In this study, we retrospectively reviewed the changes in four variables during AMI in a pig model to assess their ability to help predict AMI onset. AMI was created in 33 pigs by 90-min balloon occlusion of the left anterior descending artery. Blood pressure, EKG, and lactate and cardiac troponin I levels were recorded during the occlusion period. Blood pressure declined significantly within 15 min after balloon inflation (mean arterial pressure, from 61 ± 8 to 50 ± 8 mmHg) and remained at this low level. Within 5 min of balloon inflation, the EKG showed ST-elevation in precordial leads V1–V3. Blood lactate levels increased gradually after occlusion and peaked at 60 min (from 1.48 to 2.53 mmol/L). The continuous transdermal troponin sensor demonstrated a gradual increase in troponin levels over time. Our data suggest that significant changes in key indicators (blood pressure, EKG leads V1–V3, and lactate and troponin levels) occurred at the onset of AMI. Monitoring of these variables could be used to develop an algorithm and alert patients early at the onset of AMI with the help of a wearable device.
Background: Non-ST segment elevation acute coronary syndrome (NSTE-ACS) is conventionally diagnosed using electrocardiography and serial blood biomarker measurements. We investigated a noninvasive, bloodless, and electrode-free diagnostic strategy using a wrist-worn infrared spectrophotometric biosensor (Infrasensor). Results: In a prospective multicenter study of 595 patients with suspected NSTE-ACS enrolled across 13 sites in two countries, participants were stratified into five analytical cohorts. With 200 multi-ethnic controls and a leave-one-cohort-out external validation, a machine learning model detected high-grade coronary obstruction with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% CI: 0.84–0.90), 90% specificity, and 84% positive predictive value—surpassing standard risk scores. A secondary model predicted freedom from NSTE-ACS and adverse outcomes over 30 days with an AUC of 0.89 (95% CI: 0.87–0.92), 99% sensitivity, and 96% negative predictive value. Conclusions: The Infrasensor demonstrated high diagnostic accuracy for high-grade coronary obstruction and 30-day adverse outcome prediction, surpassing conventional risk scores across a prospective, multi-ethnic, multicenter cohort. These findings support its potential as a rapid, noninvasive point-of-care tool for early NSTE-ACS risk stratification.
Object: Transdermal biosensors may provide an alternative to conventional blood-based biomarker measurement. Our purpose was to determine the binary correlation between transdermal (Infrasensor; RCE, Inc, Carlsbad, CA) and conventional blood-based measurements. Methods: This was a secondary analysis from a previously published observational cardiac troponin I (cTnI) study performed to establish the upper reference level of cTnI, at 10 US hospitals. After obtaining informed consent, 2 cohorts of patients were enrolled: 1) those who completed a health assessment questionnaire and appeared healthy, and 2) those with a known elevated cTnI per the local hospital standard assay. All blood lab analyses were performed at the University of Maryland Medical Center, Baltimore, MD. Normal was defined as cTnI <53.48 ng/L (male) or 34.11 ng/L (female) using the Siemens Atellica IM assay (Siemens Medical Solutions, Mountain View, CA), NT-proBNP 75 years) or <124 pg/mL (1.17 mg/dL (male) or >0.95 mg/dL (female), and HbA1c <6.4%. The Infrasensor was placed on the patient's wrist for measurement and blood drawn for analysis at approximately the same time. Results: Of 840 enrolled patients, the median (IQR) age was 46 (30,57), 416 (49.5%) were female, 10.36% Hispanic, 6.7% Asian, 12.9% African American, and 69.1% White. Elevated lab tests were 102 hscTnI's, 156 NTproBNP's, 37 HbA1C's, and 163 creatinine's. Significant binary correlations were found between all transdermal signals and the corresponding lab blood levels Conclusion: Infrasensor transcutaneous measurement demonstrates similar results as that obtained from blood testing in the central laboratory.